Werkgroep Cardiologische centra Nederland

COMMANDER (Completed)

Oral Rivaroxaban vs placebo for the prevention of CV events in chronic congestive HF subjects with significant obstructive CAD
Medicine
rivaroxaban
Population
ASCVD
Phase
III
Starting year
2013
More information
ClinicalTrials.gov

Director of Study

dr. D.J.A. Lok (Cardioloog)
Deventer, Deventer Ziekenhuis